

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Novartis Bioventures Ltd			2. Issuer Name and Ticker or Trading Symbol Akouos, Inc. [AKUS]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) _____ Former 10% Owner		
(Last) _____ (First) _____ (Middle) _____ FORUM 1-1.32, LICHTSTRASSE 35			3. Date of Earliest Transaction (Month/Day/Year) 06/30/2020					
(Street) BASEL V8 CH-4056			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person _____ <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
(City) _____ (State) _____ (Zip) _____								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/30/2020		C		856,262	A	(1)	856,262	I	See Footnote ⁽²⁾
Common Stock	06/30/2020		C		199,996	A	(3)	1,056,258	I	See Footnote ⁽²⁾
Common Stock	06/30/2020		P		125,000	A	\$17	1,181,258	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	06/30/2020		C		856,262		(1)	(1)	Common Stock	856,262	\$0.00	0	I	See Footnote ⁽²⁾
Series B Preferred Stock	(3)	06/30/2020		C		199,996		(3)	(3)	Common Stock	199,996	\$0.00	0	I	See Footnote ⁽²⁾

1. Name and Address of Reporting Person* Novartis Bioventures Ltd		
(Last) _____ (First) _____ (Middle) _____ FORUM 1-1.32, LICHTSTRASSE 35		
(Street) BASEL V8 CH-4056		
(City) _____ (State) _____ (Zip) _____		
1. Name and Address of Reporting Person* NOVARTIS AG		
(Last) _____ (First) _____ (Middle) _____ FORUM 1-1.32, LICHTSTRASSE 35		
(Street) BASEL V8 CH-4056		
(City) _____ (State) _____ (Zip) _____		

Explanation of Responses:

- On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

Novartis Bioventures Ltd., By:
/s/ Bart Dzikowski, Title:
Secretary of the Board, By: /s/ 07/02/2020
Beat Steffen, Title: Authorized
Signatory.

Novartis AG, By: /s/ Bart
Dzikowski, Title: Authorized
Signatory, By: /s/ Beat Steffen, 07/02/2020
Title: Authorized Signatory.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.